Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Newegg Commerce Inc (NEGG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Newegg Commerce IncTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Newegg Commerce Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Newegg Commerce Inc trades at $11.69 (market cap $243.30M), while Vertex Pharmaceuticals Incorporated trades at $508.7 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 524.2× Newegg Commerce Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Newegg Commerce Inc for 14 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.

NEGGVRTX
Market Cap
$243.30M$127.55B
Volume
41,2521,487,944
Sector
Consumer CyclicalHealth
52-Week High
$92.74$557.96
52-Week Low
$11.49$407.37
Typical Hold Time
14 Days120 Days
Enterprise Value
$213.53M$121.68B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Newegg Commerce Inc

NEGG stock trades at $12.01, up 0.84% today, but technical indicators are bearish with moving averages signaling a downtrend. The company shows improving fundamentals, with revenue of $1.44B in 2025 and a net income margin turning positive to 0.68% in 2026 projections. Recent news highlights partnerships with Western Digital and Hewlett Packard Enterprise to support IT infrastructure, though insider selling has created negative sentiment.

The outlook is mixed; earnings beats and margin improvement offer upside, but the stock faces bearish technicals and a consensus price target of $7.75 below the current price. Key risks include volatile cash flows and high liabilities, while a single analyst rates it Buy. Investors should weigh operational progress against valuation concerns and market sentiment.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.

Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NEGG
100% Buy0% Sell
Avg holding period · 14 Days
VRTX
100% Buy0% Sell
Avg holding period · 120 Days

About Newegg Commerce Inc

Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.

Read more on NEGG →

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX →